This case identifies a rare LPL gene mutation associated with familial combined hyperlipidemia and an atypical lipodystrophy phenotype that is highly resistant to standard lipid-lowering therapies.
May prompt LPL sequencing in refractory hyperlipidemia with lipodystrophy; leaves open validation and targeted therapies.
A female patient from India was diagnosed with diabetes at 16 years of age and presented to a tertiary care diabetes clinic nine months later with hyperglycemia and dyslipidemia (hypercholesterolemia and hypertriglyceridemia), while on insulin and statin therapy. The striking feature was the presence of lipodystrophy on both her upper and lower limbs. Both her elder brother and mother showed the presence of dyslipidemia and a normal phenotype on cascade screening. All three of them had a normal BMI. Managing the case was challenging due to the suboptimal response of dyslipidemia to the various combinations of medication. Genetic testing revealed a rare mutation in the LPL gene, causing familial combined hyperlipidemia (FCH) with an unusual association of lipodystrophy. A similar heterozygous mutation was found in the mother. We report the first case of FCH with lipodystrophy from India and share the challenges encountered during the three years of follow-up.
No takes yet. Share an insight, caveat, or question.
Bhade et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: